# US 2019/0315740 A1 · Compounds and method for blocking transmission of malarial parasite

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315740 A1
- Document ID: US20190315740A1
- Status: Published application
- Kind: A1
- Application number: 16/341,000
- Filed: 2017-10-13
- Published: 2019-10-17
- Earliest claimed: 2016-10-13
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services; Loyola University of Chicago
- Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services; Loyola University of Chicago
- Inventors: Wenwei Huang; Hao Li; Wei Sun; Xiuli Huang; Paresma R. Patel; Hangmao Sun; Wei Zheng; Xiao Lu; Philip E. Sanderson; Myunghoon Kim; Meghan J. Orr; Gregory J. Tawa; Kim C. Williamson
- Web page: https://patentgrep.com/patent/US20190315740A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 33/06: Antimalarials
- C07D 487/04: Ortho-condensed systems
- C07D 487/08: Bridged systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed are compounds of formula (I) and formula (II): (I) (II) wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.

## Claims

### Claim 1

A compound of formula (I):
wherein A is CR5 or N,
B is CR3═CR4 or NR6,
R1 is C6-10 aryl or heteroaryl substituted with at least one substituent selected from —CN, cyanomethyl, —SO2R13, —SO2NHR15, and —CONR11R12, optionally further in combination with one or more substituents selected from halo, C1-12 alkyl, alkoxy, a heterocyclyl group selected from the group consisting of optionally substituted piperazinyl, morpholinyl, pyrrolinidyl, and diazepinyl, or an aryl bicyclic lactam of the formula:
wherein the aryl group of the aryl bicyclic lactam is optionally substituted with at least one substituent selected from —CN, cyanomethyl, —SO2R13, —SO2NH2, and —CONR11R12 optionally further in combination with one or more substituents selected from halo, C1-12 alkyl, alkoxy, 2-(dimethylamino)ethyl)amino, dimethylamino, a heterocyclyl group selected from the group consisting of optionally substituted piperazinyl, morpholinyl, pyrrolinidyl, azetidinyl and diazepinyl,
R2 is selected from 2-amino-5-pyridinyl, 4-pyridinyl, 2-amino-5-pyrimidinyl, 3-pyridyl, quinolin-3-yl, 5-pyrimidinyl, 2-acetylamino-5-pyridyl, 2-amino-4-methylpyrimidin-5-yl, 1-piperazinyl, indol-5-yl, 1H-imdazol-5-yl, 4-aminophenyl, 1,2,3,6-tetrahydropyridin-4-yl, 1H-pyrazol-4-yl, N-methyl-pyrazol-4-yl, 1H-benzo[d]imidazol-5-yl, 4-sulfonylaminophenyl, 2-dimethylaminopyrimidin-5-yl, 3-trifluoromethylphenyl, bromo, 3-aminophenyl, vinyl, 4-aminocarbonylphenyl, 3-cyanophenyl, 3-hydroxyphenyl, 3-trifluoromethyl-5-pyridyl, tetrazolyl, 4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, 3-aminocarbonylphenyl, 3-acetylphenyl, 3-cyano-4-chlorophenyl, 3-cyano-5-methylphenyl, 3-hydroxy-4-chlorophenyl, 4-hydroxymethylphenyl, 3-amino-4-chlorophenyl, 2,3-dihydrobenzofuran-6-yl, 1-methyl-1H-indol-5-yl, benzo[d][1,3]dioxo-5-yl, 4-fluorophenyl, 4-hydroxyphenyl, morpholin-1-yl, benzo[b]thiophen-1-yl, 4-methylsulfonylphenyl, benzo[c][1,2,5]oxadiazol-5-yl, 2-(piperidin-1-yl)-3-pyridinyl, 4-carboxyphenyl, 2-methyl-5-pyridyl, 4-methylsulfonylphenyl, 4-dimethylaminocarbonylphenyl, 4-phenylphenyl, 4-methylphenyl, 3-chloro-5-pyridyl, (3-pyrrolidin-1-yl)phenyl, 4-([piperizin-1-yl]carbonyl)phenyl, 4-([morpholin-1-yl]carbonyl)phenyl, 2-hydroxypyrimidin-5-yl, 3-aminosulfonylphenyl, 2-oxo-1,2,3,4,tetrahydroisoquinolin-6-yl, 2-oxo-1,2,3,4,-tetrahydroquinolin-6-yl, 4-(methylaminocarbonyl)phenyl, 1-oxoindolin-5-yl, 2-oxoindolin-5-yl, 1-oxoisoindolin-5-yl, 2-amino-4-pyridyl, 4-aminomethylphenyl, 3-methoxy-4-chlorophenyl, 3-methylphenyl, 3-methoxyphenyl, phenyl, 5-indolinone, 5-isoindolinone, 2-hydroxy-4-chlorophenyl, 4-cyanophenyl, 4-azetidinylphenyl, 4-ethylphenyl, 3-fluorophenyl, 3-chlorophenyl, 3-dimethylaminomethylphenyl, 3-cyano-4-fluorophenyl, 3-amino-4-fluorophenyl, 4-(1-hydroxy-1-ethylphenyl, 3-methyl-5-pyridyl, 2-acetylamio-5-pyridyl, 2-oxoindolin-5-yl, benzimidazolin-5-yl, 3-dimethylamino-1-propargyl, 2-pyrrolyl, N-methyl-2-pyrrolyl, 2-thiopheneyl, 3-thiopheneyl, 3-furanyl, and 3-aminosulfonylphenyl,
R3 and R4 are independently selected from hydrogen, hydroxyl, OR5, halogen, optionally substituted C6-10 aryl, and optionally substituted C1-6 alkyl,
R5 is hydrogen, C1-12 alkyl, C6-10 aryl, halogen, hydroxyl, or OR16,
R6 is hydrogen, C1-12 alkyl, C2-12 hydroxyalkyl, C1-6 acyl-C1-6 alkyl, or C6-10 aryl,
R7-R10 are independently selected from hydrogen, C1-12 alkyl, C3-8 cycloalkyl, CH2COOR13, and H2N(CH2)n— wherein n is an integer of 2-6,
R11 and R12 selected from the group consisting of hydrogen, C1-12 alkyl and C3-10 cycloalkyl or, taken together with the N to which they are bound, form an optionally substituted 4-7 membered heterocyclyl ring containing O or N atoms, and
R13 is C1-12 alkyl,
R15 is hydrogen or C1-12 alkyl,
R16 is C1-12 alkyl, C1-6 acyl, or C6-10 aryl,
or a pharmaceutically acceptable salt thereof,
with the proviso that when A is CH, B is CR3═CR4, R3 and R4 are each hydrogen, and R2 is 2-amino-5-pyridyl, R1 is not 3-cyanophenyl or 3-aminosulfonylphenyl.

### Claim at position 2

-7. (canceled)

### Claim 8 (depends on 1)

The compound or salt of claim 1, wherein A is CH, B is CR3═CR4, R1 is C6-10 aryl substituted with —SO2R13, R2 is selected from 4-chlorophenyl, 3-hydroxy-4-chlorophenyl, 3-amino-4-chlorophenyl, 4-fluorophenyl 4-dimethylaminomethylphenyl, 4-aminomethylphenyl, 3-methyl-4-chlorophenyl, 3-methoxy-4-chlorophenyl, 3-cyano-4-chlorophenyl, and 4-pyrrolidinomethylphenyl, and R1 is selected from 4-methylsulfonylphenyl, 4-ethylsulfonylphenyl, 2-methyl-4-methylsulfonylphenyl, and 3-piperazinylmethyl-4-methylsulfonylphenyl.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11 (depends on 8)

The compound or salt of claim 8, wherein the compound is selected from:

### Claim 12 (depends on 1)

The compound or salt of claim 1, wherein A is CH, B is CR3═CR4, R1 is C6-10 aryl substituted with —SO2N2, R2 is 4-chlorophenyl or 2-amino-5-pyridiyl, R1 is 4-aminosulfonylphenyl or 3-aminosulfonylphenyl.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The compound or salt of claim 1, wherein A is CH, B is CR3═CR4, R1 is C6-10 aryl substituted with —CONR11R12, R2 is selected from 4-chlorophenyl, 4-fluorophenyl, 4-dimethylaminomethylphenyl, 4-aminomethylphenyl, 3-amino-4-chlorophenyl, 3-hydroxy-4-chlorophenyl, 4-aminophenyl, 4-hydroxyphenyl, 4-hydroxymethylphenyl, 3-methylphenyl, 3-methoxyphenyl, 3-cyanophenyl, phenyl, 5-indolinone, 3-hydroxyphenyl, 5-isoindolinone, 3-aminophenyl, 2-hydroxy-4-chlorophenyl, 3-cyano-4-chlorophenyl, 4-cyanophenyl, 4-(2-aminoethyl)phenyl, 4-(2-dimethylaminoethyl)phenyl, 4-azetidinylphenyl, 4-ethylphenyl, 2-amino-5-pyridyl and 4-(1-aminocycloprop-1-yl)phenyl, and R1 is selected from 4-methylcarbonylaminophenyl, 4-morpholinocarbonylphenyl, 4-dimethylaminocarbonylphenyl, 4-(3,5-dimethylaminomorpholino)carbonylphenyl, 4-(4-methylpiperazinyl)carbonylphenyl, 4-piperazinylcarbonylphenyl, 4-piperidinylcarbonylphenyl, 4-[N,N-bis(2-hydroxyethyl]carbonylphenyl, 4-cyclopentylaminocarbonylphenyl, 4-azetidinylcarbonylphenyl, 4-(4-hydroxyethylpiperazinyl)carbonylphenyl, 2-methyl-4-methylaminocarbonylphenyl, 3-chloro-4-methylaminocarbonylphenyl, 4-cyclopropylaminocarbonylphenyl, 4-dimethylaminocarbonylphenyl, 4-1-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)carbonylphenyl, 4-1-(3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)carbonylphenyl, 1-(5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)carbonylphenyl, 1-(5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)carbonylphenyl, 4-(N-cyclopropyl-N-cyclohexylamino)carbonylphenyl, 4-(N-methyl-N-cyclopropylamino)carbonylphenyl, 4-cyclobutylaminocarbonylphenyl, 2-trifluoroethylaminocarbonylphenyl, 4-(2-dimethylaminoethylaminocarbonyl)phenyl, 4-(4-[2-dimethylaminoethyl]piperazin-1-yl-carbonyl)phenyl, 4-cyclopropylaminocarbonylphenyl 4-(1-[2-dimethylaminoethyl]piperidin-4-amino)carbonylphenyl, 4-(N-(1-(2-hydroxyethyl)azetidin-3-ylamino)carbonylphenyl, and 4-(pyrrolidinyl-3-amino)carbonylphenyl.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

The compound or salt of 15, wherein the compound is selected from:

### Claim 19 (depends on 1)

The compound or salt of claim 1, wherein A is CH, B is CR3═CR4, R1 is a aryl bicyclic lactam of the formula:
R7, R8, R9, and R10 are hydrogen, C1-12 alkyl, or H2N(CH2)n— wherein n is an integer of 2-6, and R2 is selected from 4-chlorophenyl, 4-dimethylaminomethylphenyl, 4-diethylaminomethylphenyl, 4-fluorophenyl, 2-amino-5-pyridyl, and 4-(1-aminocycloprop-1-yl)phenyl.

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

The compound or salt of 19, wherein the compound is selected from:

### Claim 23 (depends on 1)

The compound or salt of claim 1, wherein B is NR6, A is CH, R1 is C6-10 aryl substituted with —CN, R6 is hydrogen or methyl, R2 is selected from 4-chlorophenyl, 3-fluorophenyl, 3-chlorophenyl, 3-methoxy-4-chlorophenyl, 3-aminophenyl, 3-methylphenyl, 3-dimethylaminomethylphenyl, 3-cyano-4-fluorophenyl, 3-hydroxy-4-fluorophenyl, 3-methoxy-4-fluorophenyl, 3-cyano-4-chlorophenyl, 3-hydroxy-4-chlorophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-hydroxyphenyl, 3-amino-4-fluorophenyl, 4-dimethylaminophenyl, 4-methylphenyl, 4-aminophenyl, 4-(1-hydroxy-1-ethyl)phenyl, 4-(2-aminoethyl)phenyl, 2-amino-5-pyridyl, 2-amino-5-pyrimidyl, 2-methyl-5-pyridyl, 2-acetylamino-5-pyridyl, 2-oxoindolin-5-yl, benzimidazolin-5-yl, 3-dimethylamino-1-propargyl, 4-(2-dimethylaminoethyl)phenyl, 2-pyrrolyl, N-methyl-2-pyrrolyl, 2-thiopheneyl, 3-thiopheneyl, 3-furanyl, 3-aminosulfonylphenyl, and 4-dimethylaminomethylphenyl, and R1 is selected from 3-cyano-6-methyl phenyl, 3-cyano-4-piperazinyl-6-methylphenyl, 3-cyanophenyl, 3-cyano-4-piperazinylphenyl, 3-cyano-4-morpholinylphenyl, 4-(4-(2-hydroxyethylpiperazinyl-3-cyanophenyl, 3-cyano-4-(1,4-diazepan-1-yl)phenyl, 3-cyano-4-(4-acetylaminopiperazin-1-yl), 2-methyl-3-cyanophenyl, 3-cyano-4-(3-aminoazetidinyl)-6-methylphenyl, 3-cyano-4-(2-dimethylaminoethyl)-6-methylphenyl, 2-piperazinyl-3-cyano-6-methyl-5-pyridyl, 2-piperazinyl-3-cyano-5-pyridyl, 3-cyano-4-methoxyphenyl, 3-cyano-4-(4-hydroxypiperidinyl)phenyl, 3-cyano-4-(4-aminopiperidinyl)phenyl, and 2-methyl-3-cyanophenyl.

### Claim at position 19

-27. (canceled)

### Claim 28 (depends on 23)

The compound or salt of claim 23, wherein the compound is selected from:

### Claim 29 (depends on 1)

The compound or salt of claim 1, wherein B is NR6, A is CH, R1 is C6-10 aryl substituted with —SO2R13, R2 is 2-amino-5-pyridyl or 4-chlorophenyl, and R1 is 4-aminosulfonylphenyl.

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32 (depends on 29)

The compound or salt of claim 29, wherein the compound is:

### Claim 33 (depends on 1)

The compound or salt of claim 1, wherein B is NR6, A is CH, R1 is C6-10 aryl substituted with —CONR11R12, R2 is selected from 4-chlorophenyl, 2-amino-5-pyridyl, 3-hydroxy-4-chlorophenyl, 4-fluorophenyl, 3-cyanophenyl, 4-dimethylaminomethylphenyl, and 4-methylphenyl, and R1 is 4-morpholinocarbonylphenyl, 4-dimethylaminocarbonylphenyl, 4-(N-methyl-N-cyclopropyl)aminocarbonylphenyl, or 4-piperidinocarbonylphenyl.

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36 (depends on 33)

The compound or salt of claim 33, wherein the compound is selected from:

### Claim 37 (depends on 1)

The compound or salt of claim 1, wherein B is NR6, A is CH, R1 is:
and R2 is 4-chlorophenyl or 4-dimethylaminophenyl.

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40 (depends on 1)

A pharmaceutical composition comprising a compound or salt of claim 1 and a pharmaceutically acceptable carrier.

### Claim 41 (depends on 1)

A method of blocking transmission of a Plasmodium parasite or treating malaria by killing or arresting the growth of Plasmodium organisms in a mammal, wherein the Plasmodium organisms are in a gametocyte stage comprising administering to a mammal in need of such treatment, a therapeutically effective amount of a first compound of claim 1, optionally in combination with an antimalarial compound selected from elesclomol, NSC174938, NVP-AUY922, maduramicin, narasin, alvespimycin, omacetaxine, thiram, zinc pyrithione, phanquinone, bortezomib, salinomycin sodium, monensin sodium, dipyrithione, dicyclopentamethylene-thiuram disulfide, YM155, withaferin A, adriamycin, romidepsin, AZD-1152-HQPA, CAY10581, plicamycin, CUDC-101, auranofin, trametinib, GSK-458, afatinib, and panobinostat.

### Claim at position 34

-44. (canceled)

### Claim 45

A compound of formula (II):
wherein A is CR5 or N,
wherein R1 is C6-10 aryl or heteroaryl substituted with one or more substituents selected from the group consisting of C1-12 alkyl, C3-10 cycloalkyl, alkoxy, —CF3, heterocyclyl, —CONR11R12, —SO2NHR16, and CN,
R2 is selected from 2-amino-5-pyridinyl, 4-pyridinyl, 2-amino-5-pyrimidinyl, 3-pyridyl, quinolin-3-yl, 5-pyrimidinyl, 2-acetylamino-5-pyridyl, 2-amino-4-methylpyrimidin-5-yl, 1-piperazinyl, indol-5-yl, 1H-indazol-5-yl, 4-aminophenyl, 1,2,3,6-tetrahydropyridin-4-yl, 1H-pyrazol-4-yl, 1H-benzo[d]imidazol-5-yl, 4-sulfonylaminophenyl, 2-dimethylaminopyrimidin-5-yl, 3-trifluoromethylphenyl, bromo, 3-aminophenyl, vinyl, 4-aminocarbonylphenyl, 3-cyanophenyl, 3-trifluoromethyl-5-pyridyl, tetrazolyl, 4-chlorophenyl, 4-methoxyphenyl, 3-aminocarbonylphenyl, 3-acetylphenyl, 2,3-dihydrobenzofuran-6-yl, 1-methyl-1H-indol-5-yl, benzo[d][1,3]dioxo-5-yl, 4-fluorophenyl, 4-hydroxyphenyl, morpholin-1-yl, benzo[b]thiophen-1-yl, 4-methylsulfonylphenyl, benzo[c][1,2,5]oxadiazol-5-yl, 2-(piperidin-1-yl)-3-pyridinyl, 4-carboxyphenyl, 2-methyl-5-pyridyl, 4-methylsulfonylphenyl, 4-dimethylaminocarbonylphenyl, 4-phenylphenyl, 4-methylphenyl, 3-chloro-5-pyridyl, (3-pyrrolidin-1-yl)phenyl, 4-([piperizin-1-yl]carbonyl)phenyl, 4-([morpholin-1-yl]carbonyl)phenyl, 2-hydroxypyrimidin-5-yl, 3-aminosulfonylphenyl, 2-oxo-1,2,3,4,tetrahydroisoquinolin-6-yl, 2-oxo-1,2,3,4,-tetrahydroquinolin-6-yl, 4-(methylaminocarbonyl)phenyl, 1-oxoindolin-5-yl, 2-oxoindolin-5-yl, and 1-oxoisoindolin-5-yl,
R11 and R12 selected from the group consisting of hydrogen, C1-12 alkyl and C3-10 cycloalkyl or, taken together with the N to which they are bound, form an optionally substituted 4-7 membered heterocyclyl ring containing O or N atoms,
R14 is hydrogen or C1-12 alkyl, and
R16 is hydrogen or C1-12 alkyl,
or a pharmaceutically acceptable salt thereof.

### Claim at position 36

-48. (canceled)

### Claim 49 (depends on 45)

A pharmaceutical composition comprising a compound or salt of claim 45 and a pharmaceutically acceptable carrier.

### Claim 50 (depends on 45)

A method of blocking transmission of a Plasmodium parasite or by killing or arresting the growth of Plasmodium organisms in a mammal, wherein the Plasmodium organisms are in a gametocyte stage comprising administering to a mammal in need of such treatment, a therapeutically effective amount of a first compound of claim 45, optionally in combination with an antimalarial compound selected from elesclomol, NSC174938, NVP-AUY922, maduramicin, narasin, alvespimycin, omacetaxine, thiram, zinc pyrithione, phanquinone, bortezomib, salinomycin sodium, monensin sodium, dipyrithione, dicyclopentamethylene-thiuram disulfide, YM155, withaferin A, adriamycin, romidepsin, AZD-1152-HQPA, CAY10581, plicamycin, CUDC-101, auranofin, trametinib, GSK-458, afatinib, and panobinostat.

### Claim at position 39

-57. (canceled)
